STOCK TITAN

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)

WuXi AppTec announced that its Active Pharmaceutical Ingredient (API) manufacturing sites in Changzhou and Taixing, China, have successfully passed U.S. FDA inspections in March 2025 with no observations or Form 483 issues.

The Changzhou facility's GMP surveillance inspection covered 21 FDA-approved products, while Taixing completed a Pre-Approval Inspection for commercial manufacturing of a peptide-based therapeutic. The 169-acre Taixing site, operational since September 2023, is the company's newest and largest API manufacturing facility.

WuXi AppTec is expanding globally with recent developments including:

  • Doubled oral dose capacity at Couvet, Switzerland facility in 2024
  • Ongoing construction of Middletown, Delaware site (operations expected by 2026)
  • New Singapore R&D and manufacturing site groundbreaking (Phase I operations planned for 2027)

WuXi AppTec ha annunciato che i suoi siti di produzione di Ingredienti Farmaceutici Attivi (API) a Changzhou e Taixing, in Cina, hanno superato con successo le ispezioni della FDA degli Stati Uniti nel marzo 2025, senza osservazioni o problemi con il modulo 483.

L'ispezione di sorveglianza GMP della struttura di Changzhou ha coperto 21 prodotti approvati dalla FDA, mentre Taixing ha completato un'Ispezione Pre-Approva per la produzione commerciale di un terapeutico a base di peptide. Il sito di Taixing, che si estende su 169 acri e operativo da settembre 2023, è il più recente e il più grande impianto di produzione di API dell'azienda.

WuXi AppTec sta espandendo la sua presenza globale con sviluppi recenti che includono:

  • Capacità di dosaggio orale raddoppiata presso l'impianto di Couvet, in Svizzera, nel 2024
  • Costruzione in corso del sito di Middletown, Delaware (operazioni previste entro il 2026)
  • Inizio dei lavori per un nuovo sito di R&S e produzione a Singapore (operazioni della Fase I previste per il 2027)

WuXi AppTec anunció que sus sitios de fabricación de Ingredientes Farmacéuticos Activos (API) en Changzhou y Taixing, China, han pasado con éxito las inspecciones de la FDA de EE. UU. en marzo de 2025, sin observaciones ni problemas con el Formulario 483.

La inspección de vigilancia GMP de la instalación de Changzhou cubrió 21 productos aprobados por la FDA, mientras que Taixing completó una Inspección Pre-Aprobación para la fabricación comercial de un terapéutico basado en péptidos. El sitio de Taixing, que abarca 169 acres y está en operación desde septiembre de 2023, es la instalación de fabricación de API más nueva y grande de la empresa.

WuXi AppTec está expandiéndose globalmente con desarrollos recientes que incluyen:

  • Capacidad de dosis oral duplicada en la instalación de Couvet, Suiza, en 2024
  • Construcción en curso del sitio de Middletown, Delaware (se espera que las operaciones comiencen en 2026)
  • Inicio de la construcción de un nuevo sitio de I+D y fabricación en Singapur (se prevé que las operaciones de la Fase I comiencen en 2027)

우시 앱텍은 중국 창저우와 타이싱에 있는 활성 제약 성분(API) 제조 시설이 2025년 3월 미국 FDA 검사를 성공적으로 통과했으며, 관찰 사항이나 483 양식 문제 없이 진행되었다고 발표했습니다.

창저우 시설의 GMP 감시 검사에서는 FDA 승인을 받은 21개 제품이 포함되었으며, 타이싱은 펩타이드 기반 치료제의 상업 제조를 위한 사전 승인 검사를 완료했습니다. 169에이커 규모의 타이싱 사이트는 2023년 9월부터 운영되고 있으며, 회사의 최신이자 가장 큰 API 제조 시설입니다.

우시 앱텍은 최근의 발전을 통해 글로벌 확장을 진행 중입니다. 여기에는:

  • 2024년 스위스 쿠베에서 경구 용량을 두 배로 증가
  • 델라웨어 미들타운 사이트의 건설 진행 중(2026년 운영 예정)
  • 싱가포르에서의 새로운 연구개발 및 제조 사이트 착공(1단계 운영이 2027년 예정)

WuXi AppTec a annoncé que ses sites de fabrication d'Ingrédients Pharmaceutiques Actifs (API) à Changzhou et Taixing, en Chine, ont réussi les inspections de la FDA américaine en mars 2025, sans observations ni problèmes avec le formulaire 483.

L'inspection de surveillance GMP de l'installation de Changzhou a couvert 21 produits approuvés par la FDA, tandis que Taixing a complété une Inspection Pré-Autorisation pour la fabrication commerciale d'un thérapeutique à base de peptide. Le site de Taixing, s'étendant sur 169 acres et opérationnel depuis septembre 2023, est le plus récent et le plus grand site de fabrication d'API de l'entreprise.

WuXi AppTec s'étend à l'échelle mondiale avec des développements récents comprenant :

  • Capacité de dosage oral doublée à l'installation de Couvet, en Suisse, en 2024
  • Construction en cours du site de Middletown, Delaware (les opérations devraient débuter en 2026)
  • Début de la construction d'un nouveau site de R&D et de fabrication à Singapour (les opérations de la phase I sont prévues pour 2027)

WuXi AppTec gab bekannt, dass seine Produktionsstätten für aktive pharmazeutische Inhaltsstoffe (API) in Changzhou und Taixing, China, im März 2025 erfolgreich die FDA-Inspektionen der USA bestanden haben, ohne Beobachtungen oder Probleme mit dem Formular 483.

Die GMP-Überwachungsinspektion der Einrichtung in Changzhou umfasste 21 von der FDA genehmigte Produkte, während Taixing eine Vorabgenehmigungsinspektion für die kommerzielle Herstellung eines peptidbasierten Therapeutik abgeschlossen hat. Das 169 Hektar große Gelände in Taixing, das seit September 2023 in Betrieb ist, ist die neueste und größte API-Produktionsstätte des Unternehmens.

WuXi AppTec expandiert global mit aktuellen Entwicklungen, die Folgendes umfassen:

  • Verdopplung der oralen Dosierungskapazität in der Anlage in Couvet, Schweiz, im Jahr 2024
  • Fortschreitender Bau des Standorts Middletown, Delaware (Betrieb wird für 2026 erwartet)
  • Baubeginn eines neuen Forschungs- und Entwicklungs- sowie Produktionsstandorts in Singapur (Betrieb der Phase I ist für 2027 geplant)

Positive
  • Successfully passed FDA inspections at two major API manufacturing sites with zero observations
  • Operational approval for commercial manufacturing of peptide-based therapeutic at Taixing facility
  • Significant global expansion with new facilities in Switzerland, USA, and Singapore
  • Portfolio includes 21 FDA-approved products at Changzhou facility
Negative
  • None.

SHANGHAI, March 31, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industry, today announced that its Active Pharmaceutical Ingredient (API) manufacturing sites at Changzhou and Taixing in Jiangsu province of China, successfully passed U.S. Food and Drug Administration (FDA) inspections back-to-back in March — both without a single observation and with no Form 483 issued. These achievements further demonstrate WuXi AppTec's unwavering commitment to upholding the highest quality standards and to supporting global healthcare innovators in reliably delivering needed therapies to patients worldwide.

The Company's API site at Changzhou underwent a GMP surveillance inspection by the FDA that began on March 4. Covering 21 FDA-approved products, the inspection followed the FDA's six-system inspection model. The FDA inspectors concluded the review one day ahead of schedule. No observation was raised.

On March 21, 2025, the API site at Taixing also completed a Pre-Approval Inspection (PAI) for the commercial manufacturing of a peptide-based therapeutic, with no observation. The site presented its state-of-the-art infrastructure, the team's strong technical expertise, and the high level of compliance demonstrated through its systems, documentation, and records. Operational since September 2023, the 169-acre Taixing site is the company's newest and largest API manufacturing facility. The successful inspection confirms the site's readiness to support commercial API supply to the global market.

"Our team's consistent focus on quality and compliance is key to enabling our global partners," said Dr. Minzhang Chen, Co-CEO of WuXi AppTec. "We're pleased that both the Changzhou and Taixing sites passed their FDA inspections with no observation. These successful results further reinforce WuXi AppTec's dedication to providing high-quality R&D and manufacturing solutions that support our customers worldwide in accelerating new drug development and commercialization for the benefit of patients."

The Changzhou and Taixing sites are critical manufacturing bases of WuXi STA, the company's small molecule CDMO platform, and WuXi TIDES, which provides integrated CRDMO services for oligonucleotides, peptides, and synthetic conjugates. Both sites support the manufacturing of APIs and intermediates across a wide range of chemical modalities.

WuXi AppTec continues to invest in capacity expansion to meet growing global demand. The company's investment in its Couvet, Switzerland, site resulted in doubling oral dose capacity over the course of 2024. Meanwhile, WuXi AppTec continued to build its U.S. (Middletown, DE) site, which is expected to commence operations by the end of 2026. In May 2024, the company announced the groundbreaking of Singapore R&D and manufacturing site; Phase I expects to commence operations in 2027. 

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec's integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024 and its open-access platform is enabling around 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated." Please visit: http://www.wuxiapptec.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wuxi-apptecs-changzhou-and-taixing-api-sites-successfully-pass-fda-inspections-302415884.html

SOURCE WuXi AppTec

FAQ

What was the outcome of WuXi AppTec's FDA inspections at Changzhou and Taixing sites in March 2025?

Both sites passed FDA inspections with zero observations and no Form 483 issues, demonstrating full compliance with regulatory standards.

How many FDA-approved products are manufactured at WuXi AppTec's Changzhou facility?

The Changzhou facility manufactures 21 FDA-approved products.

What is the size and significance of WuXi AppTec's new Taixing API manufacturing facility?

The Taixing facility spans 169 acres and is the company's newest and largest API manufacturing facility, operational since September 2023.

What are WuXi AppTec's global expansion plans for 2026-2027?

The company plans to commence operations at its Middletown, Delaware site by 2026 and Phase I of its Singapore R&D and manufacturing site by 2027.

What manufacturing capabilities were expanded at WuXi AppTec's Couvet, Switzerland facility in 2024?

The Couvet facility doubled its oral dose manufacturing capacity during 2024.
Wuxi Apptec

OTC:WUXAY

WUXAY Rankings

WUXAY Latest News

WUXAY Stock Data

27.85B
2.50B
Diagnostics & Research
Healthcare
Link
China
Shanghai